Pfizer (NYSE:PFE) is reportedly mulling a sale of the infusion pump business it acquired along with Hospira last year, aiming to focus on its core branded pharmaceuticals business.
Hospira makes generic versions of injectable drugs used in hospitals, pumps to deliver them and also sells biosimilars or copies of biotech drugs. New York City-based Pfizer closed the $15 billion acquisition last September.
Citing “people with knowledge of the matter,” Bloomberg reported that the infusion pump unit could fetch as much as $2 billion.
Pfizer is in the very early stages of the process and could opt to hold on to the Hospira devices business, the sources said.
The pharma giant is is in the middle of its largest-ever buyout, a $160 billion union with Allergan (NYSE: AGN), a so-called inversion deal that would see it reincorporate in Ireland.
The post Report: Pfizer mulls sale of Hospira infusion pump biz appeared first on MassDevice.